Aim: The aim of this review is to identify a suitable cognitive screening tool that can be used by the pharmacist during home medication review in addition to calculating the medications' total anticholinergic burden (ACB).
INTRODUCTION
Cognitive function is a concept of multidimensional domains which are associated with the performance of the normal healthy brain, including psychomotor ability, concentration and attention, information processing speed, executive function, visuospatial skill, language, memory and learning. 1 Cognitive impairment is the deterioration in the function of one or a number of these domains. 2 This may be in a form of a single specific impairment or a group of related impairments. 2 Furthermore, cognitive impairment is inferred from an individual's behaviour rather than observed directly. Mild cognitive impairment (MCI), isolated memory impairment or incipient dementia is a brain function disorder which involves the evolution and onset of cognitive deficits beyond those anticipated based on the individuals' age and education, but these deficits are not significant enough to disturb the individuals' activities of daily living. 3 MCI has also been described as a transitional state between standard cognitive function and Alzheimer's disease (AD). 4 There has been a dramatic increase in the use of cognitive screening tests to provide detection tools and objective measures of cognitive functioning over the last 10 years. A substantial number of screening tests exist, including the mini-mental state examination (MMSE), the Rowland Dementia Assessment Scale (RUDAS), the Alzheimer's disease Assessment Scale -Cognition (ADASCog), Psychogeriatric Assessment Scale (PAS) and Kimberley Indigenous Cognitive Assessment (KICA-Cog), the anxiety and depression checklist (K10) and 'worried about your memory' (WAYM) ( Table 1) . Due to the effect of some medications on cognition, the pharmacist is in a good position to use the anticholinergic cognitive burden scale (ACB) to guide their advice to other health 33, 34 MMSE scores are useful in documenting cognitive change serially and in estimating the severity of cognitive impairment quantitatively. 33, 34 Despite the wide range of cognitive screening tests available, MMSE is the most widely used and popular clinical measure due to its availability in many languages. 33 The MMSE is used widely in studies and community surveys. 33 It forms part of the diagnostic interview schedule and a structured interview used recently in a large five-site epidemiological catchment area study promoted by the National Institute of Mental Health. 33, 34 Additionally, MMSE has been incorporated into several standardised interviews designed to help diagnose dementia and to assess cognitive impairment. 33, 34 The National
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association has recommended MMSE as one of the tests to document the clinical diagnosis of possible Alzheimer's disease. 33 The MMSE has a maximum score of 30 points and consists of a range of questions which can be administered ordinarily in 5-10 min. 33, 34 The questions are categorised into seven groups, each representing a different cognitive function domain. They are orientation to time (5 points), orientation to place (5 points), attention and calculation (5 points), registration of three words (3 points), recall of three words (3 points), language (8 points) and visual construction (1 point). 33 Although MMSE has been shown to fulfil its original goal of providing a brief screening test that quantitatively assesses the severity of cognitive impairment and documents cognitive changes occurring over time, it should not, by itself, be used as a diagnostic tool to identify dementia. 33 RUDAS RUDAS is a multicultural cognitive assessment scale. 35 It is a short cognitive screening instrument designed to minimise the effects of cultural learning and language diversity on the assessment of baseline cognitive performance. 35 When administering the RUDAS, it is important that the respondent is encouraged to communicate in the language with which they are most competent and comfortable. 35 Also, the test taker should be as relaxed as possible, because test anxiety can interfere with performance on cognitive tests. 35 Additionally, the RUDAS test is conducted in a quiet area, so the test taker can hear clearly. 35 It is important to identify at the start of the assessment, if the test taker has hearing problems and accommodate for this as much as possible such as speaking slowly and clearly and encouraging test takers to wear any hearing aids necessary. 35 Furthermore, RUDAS provides a large print version of the test if the test taker suffers severe hearing impairment. 35 RUDAS also ensures that the test taker is using reading glasses when necessary and that there is sufficient light in the room. 35 At the end of the RUDAS test, the scores will be added up for each item to obtain a total score out of 30. 35 Test takers with scores of 22 or less will be concluded to possibly have cognitive impairment, and will be referred on for further investigation by the relevant physician. 35 If test takers suffer a physical disability (e.g. vision,
hearing, hemiparesis, amputee, stroke, aphasia) which may affect their ability to perform certain items on the RUDAS, it is important to interpret any total score less than 22 with caution. 35 Thus, further research is necessary to assess validity of the RUDAS in this sub-group of patients.
35
ADAS-Cog It has been reported that ADAS-Cog is the most popular cognitive testing instrument used in clinical trials and a sensitive cognitive function assessment scale for Alzheimer's disease (AD). 36 Its validity and reliability have been established in the original English version. 36 ADAS-Cog consists of 11 items which are designed to measure the severity of the most important and the core symptoms of AD, including orientation, memory, praxis function and language disturbances. 37 ADAS-Cog is not designed for use as a diagnostic tool, but scores on the scale discriminate patients with clinically diagnosed AD from non-dementia subjects. 36 Its sensitivity to detect change has been documented by longitudinal followup data. 36 On average, AD patients show an increase in ADAS-Cog scores of about 7 to 8 points per yearly interval. 36 It has been reported that ADAS-Cog is more sensitive than other dementia rating scales such as Folstein MMSE. 36 Thus, ADAS-Cog is commonly employed as a primary outcome measure to assess the effects of cognitive enhancing drugs in clinical trials of new drug treatments for AD. 36 
PAS
The PAS is designed to gather information on the main psychogeriatric disorders: depression and dementia. 38, 39 PAS differs from conventional approaches to psychogeriatric assessment in a number of significant ways. 38 Psychogeriatric assessment is generally the province of people with extensive specialist training in geriatrics or psychiatry. 38 PAS aims to assist a wider range of people to carry out psychogeriatric assessment, so it provides a straightforward method of gathering and interpreting the relevant information without the necessity for prolonged training. 38, 39 Furthermore, in conventional thinking, people having depression or dementia are in a distinct group from 'normal' people. 38 It is true that when people with psychogeriatric disorders are seen by healthcare workers they appear to be categorically apparent from other people. 38 However, when the whole elderly population is looked at, depression and dementia are seen as part of a continuum. 38, 39 For instance, there is a continuum ranging from successful cognitive ageing at one end to severe dementia at the other. 38 There is a different continuum ranging from positive well-being in old age to severe depression. 38 However, the PAS aims to put people along a number of appropriate continua and helps by collecting information in a systematic way. 38 The PAS also gives guidance on how this information should be interpreted by comparing the results to professionals who can then provide the required clinical interventions. ACB is used as a research tool to examine the use of anticholinergic medications in populations at high risk, such as demented patients. Based on medications' anticholinergic properties, each medication is given a score of 1, 2 or 3. Fox et al. (2011) allocated a score of either two or three to medications which definitely possess anticholinergic effects and a score of one to medications with potential anticholinergic effects. 5 For each medication with definite anticholinergic effects Fox et al.
(2011) concluded that a 46% increase in cognitive impairment risk may result over 6 years and that the rise in the total score of ACB by one point was linked with an increased risk of death by 26% and a reduction in MMSE score of 0.33 points over 2 years. 6 
Aim
This review is a part of a parent study which aims to investigate the role of the pharmacist in early detection of medication that may compromise cognition in the elderly, during a home medication review (HMR), and early referral to a treating doctor for further action whenever possible. The aim of this review is to identify a suitable cognitive screening tool that can be used by the pharmacist during medication review in addition to calculating the medications' total ACB.
METHOD
In order to check the validity of current tools available to test cognition and the possibility of pharmacists administering these tests, a search of the literature was conducted using the PubMed, Embase, Medline and Google Scholar databases to identify relevant studies using the following keywords: 'cognitive impairment', 'cognitive impairment AND diagnosis', 'cognitive scales', 'dementia', 'delirium', 'pharmacist role', 'minimental state examination (MMSE)', 'the Rowland KICA-Cog The KICA was developed in response to the need for a validated cognitive screening tool for older Indigenous Australians living in rural and remote areas. 40 The KICA-Cog section is validated with Indigenous Australians aged 45 years and above from the Kimberley and Northern Territory. 40 The KICA-Cog has a maximum score of 39. A score of 33/39 and below indicates possible dementia. 40 Those with a low KICA-Cog score should be referred to a doctor for medical screens to rule out other causes of cognitive impairment, some of which are reversible, or to confirm dementia. 40 KICA-Cog's cognitive assessment contains the informant (carer) report which has been validated with a score of 3/16 or above indicating that further investigations are required. 40 Other sections of the KICA tool are for information gathering to assist in determining subtypes, severity, differential diagnoses and management. 40 As language skills are assessed in the cognitive section it is recommended that an interpreter be used when required. 40 Furthermore, KICA-Cog contains a visual naming task. 40 If an individual is unable to name a certain photo (crocodile or emu) because of their own cultural reasons, it can be replaced by dog or horse pictures. 40 Thus, KICA-Cog appears to be a reliable assessment tool in an Australian older traditionally living Indigenous population for cognitive impairment.
40

K10
The K10 is a simple widely recommended tool to measure psychological distress as well as outcomes after different mental health problems. The K10 is available to the public through the website of the Clinical Research Unit for Anxiety and Depression to identify who requires treatment and anyone can administer it. 41, 42 There are five responses in the 10-item scale. Score one being none of the time and score five being all of the time. Thus, total scores range from 10 which means no distress to 50 which means severe distress. 42 Composite International Diagnostic Interview (CIDI) identifies people with a score between 0 and 15 as having one-quarter of the population risk for meeting the depressive or anxiety disorder criteria. 41, 43 People with scores between 16 and 30 have 25% chance of developing a current depressive or anxiety disorder and a 1% chance of ever attempting suicide in their lives. 41, 43 People with scores between 30 and 50 have 75% chance of meeting the criteria for a depressive or anxiety disorder and a 6% chance of ever attempting suicide in their lives. 41 
WAYM
The "worried about your memory" (WAYM) is a tool developed by Alzheimer's Australia and aims to increase awareness of the early symptoms and signs of dementia. WAYM encourages people to seek help if they have memory concerns. 44 WAYM contains 12 statements which the person should comment on by choosing either rarely, sometimes or often. If a person has ticked 'sometimes' or 'often' it is recommended that he/she see his/her doctor. dementia assessment scale (RUDAS)', 'the Alzheimer's Disease Assessment Scale -Cognition (ADAS-Cog)' and 'barriers and problems'. A number of tools were identified as potential tools that can be used in the primary care setting (Table 1) . Only informational websites, clinical trials and review articles were included. These were directly related to the review and the parent study concept is listed in Tables 2  and 3 .
Literature Review
The diagnosis of different cognitive impairments is challenging. Despite the presence of different diagnostic tools to distinguish between different cognitive impairment causes and levels, getting a correct diagnosis is still considered a significant challenge. 7 For instance, delirium may be overlooked when mild, considered as part of normal aging, or incorrectly diagnosed as a psychiatric illness, e.g. depression or dementia. Many studies showed that physicians fail to recognise 32-67% of delirious patients. 7, 8 Additionally, other studies demonstrated that cognitive function is rarely formally assessed unless it is reported as an issue by the patient 9 and there is frequently minimal knowledge about the course of any cognitive impairment or the baseline cognitive status of patients. 10 Although delirium has the potential to be the sole manifestation of a serious illness, such as myocardial infarction (MI) or sepsis, it is not usually considered as a significant Health professionals tend to pay attention when a delirious patient presents with inappropriate behaviours, hallucinations and agitation, whereas delirium associated with lethargy and decreased activity is commonly missed. 10 One study found that 37% of 74 patients considered depressed by house staff consultees were actually rediagnosed by the consulting psychiatrist and found to suffer from delirium. 11 Furthermore, another study conducted by Tiamson et al. (1993) showed that about 27% of 677 depressed patients were actually suffering an organic mental disorder after they were rediagnosed by a consulting psychiatrist. 12 Another study demonstrated the low sensitivity of the diagnosis of delirium by emergency department doctors although the prevalence of delirium among elderly patients in this department is relatively high. 13 Johnson et al. (1992) noted that delirium was explicitly recognised in only 5% of studied elderly general hospital admissions. 14 Also, the study showed that 25% of the missed cases were diagnosed as a functional psychiatric disorder, while 25% of the cases were diagnosed as dementia and 50% of cases were documented as no diagnosis. 14 Patients with mild dementia can also suffer from delirium due to other underlying causes, which may worsen their quality of life sooner than if it is managed. 15 Additionally, it has been shown that hypoactive delirium, which accounts for 25% of cases, is most likely to be missed as it is mistakenly diagnosed as depression and/or its symptoms don't disturb other people. 16 One study, which was conducted in two geriatric hospitals, showed that the diagnosis of different cognitive impairments among hospitalised older patients was insufficient. 17 The cognitive impairment was recorded in medical notes in 79.5% of cases and cognitive testing was conducted on only 47.7% of patients with diagnosed dementia. 17 The detection of dementia was recorded in 47/88 dementia patients. Eight of these patients had been found to have a false-positive diagnosis. Furthermore, delirium was recorded in only 31 out of 77 delirious patients who were diagnosed by the researchers. 17 Poor documentation and detection of underlying causes may result in under-or over-treatment 17 as explicit identification of cognitive impairment such as delirium has been correlated with better outcomes in terms of lower mortality and shorter in-patient hospital stays. 18 Missing ACB as the cause, especially during short encounters with patients in the primary care setting may affect patients' management in many spheres, including patient medications. Pharmacists spend at the least 60 min with patients during the HMR process; if pharmacists can then include a validated cognition test tool and calculate the ACB to include in their final report, this may provide the treating doctor with valuable information and possible early intervention to improve patient quality of life. However, this hypothesis is yet to be tested in the parent study of this review, which the author is currently undertaking.
Medications Related Issues
Medication-related cognitive impairments arising from poor medication management can result in significant morbidity and secondary care admissions. 19 It has been demonstrated that medications contribute to about 40% of delirium cases. 20 Furthermore, medication errors and adverse drug events, including those that are related to cognition, may result in admission to intensive care units. 21 One study showed that 6.5% of all admissions to secondary care units are caused by adverse drug reactions. 19 Also, the study found that each year 6000 deaths are associated with such events in England. 19 Another study, which considered impaired cognition as the essential predictor of avoidable medication-related admissions to hospitals, showed that 5.6% of unplanned admissions were linked to medications and almost half (46.5%) of them were potentially avoidable. 22 It has been shown that people with dementia are often prescribed medications which impair and/or worsen their cognition, such as medications with sedative and/or anticholinergic activities. 23, 24 Approximately 20-50% of dementia patients have been shown to take at least one medication with anticholinergic properties. 21 Moreover, dementia patients may fail to identify potential medication errors as they are less likely to appreciate adverse reactions, ask about their prescriptions or any change in their drugs and know whether they need monitoring. 25, 26 Thus, a complete medication review should be considered to improve cognitive impairment care. 21 
Pharmacist Role in Early Detection of Cognitive Impairment
Pharmacists can play an active role in early recognition and prevention of medication-induced cognitive impairment, when considering the ACB is actually a medications adverse effect, i.e. adverse effect prevention is an integrated activity to the pharmacy profession. It has been shown that pharmacists were able to decrease the rate of preventable adverse drug reactions after discharge from hospital through patient counselling, telephone follow up and medication review. 27 Additionally, collaboration between pharmacists and doctors to investigate treatment, patient management and pharmacotherapy has been used in different countries to improve prescribing and disseminate new guidelines and knowledge. 28 One study (2001) 28 with elderly subjects showed that the use of antidepressants with highly anticholinergic activities was reduced and those with less anticholinergic properties increased through continuing medical education conducted by pharmacists and doctors. 28 Moreover, it has been demonstrated that the educational program resulted in a significant reduction in the use of antipsychotic medications, which also exhibit anticholinergic properties, with no rise in the prevalence of behavioural problems. 29 This may result in less anticholinergic burden, including medication-induced cognitive impairment. Furthermore, He and Ball showed in their theoretical study that a reduction in ACB score by 1 can be achieved in 85% of cases with scores of 3 and 59% of cases with scores of 1 by altering the medication regimen based on appropriate practice guidelines. 30 The Aging Brain Program at Indiana University also developed a guideline which is composed of a list of medications that can be used as alternatives to the medications with definite anticholinergic activities. The use of this guideline may help health professionals to provide care for individuals who suffer from cognitive impairment, including delirium, mild cognitive impairment or dementia. 31 Another study with elderly frail subjects showed that the anticholinergic drug scale (ADS) score reduced significantly after pharmacistinitiated medication changes. 32 However, the same study found that medication changes did not significantly reduce dryness of the mouth or serum anticholinergic activity (SAA).
32 Table 1 lists the commonly used assessment tools. Pharmacists do not undertake training in cognitive assessment as core skills in their undergraduate program, but their role as members of the primary care team puts cognitive assessment within the pharmacist scope of practice. Most assessment tools -not including K10 or WAYM -are not feasible to be used unless further training is completed post-graduation to be able to produce consistent interpretation of the results.
CONCLUSION
A substantial number of screening tests exist, including MMSE, RUDAS, ADAS-Cog, PAS, KICA-Cog, K10 and WAYM.
One of the pharmacist's core professional activities is to reduce medication adverse effects. ACB, when it is not the main indication of the medications prescribed to patients, is considered as a side effect. Accordingly, calculating total ACB score of patient medications theoretically can be used to guide reduction and management of medications to improve patient quality of life. However, the same score may not produce the same effect in all patients; accordingly a supporting tool to detect the effect of the score on patient cognitive functioning early is important. The pharmacist has the opportunity to spend 60 min with the patient during an HMR, and if the pharmacist calculates the ACB total score and administers the K10 and WAYM and provides those results to the treating doctor as part of the HMR report, it may guide the doctor's management of patient medication or trigger a referral of the patient for further investigations leading to better health outcomes and quality of life. However, further research is required to prove this hypothesis to be actual or null.
